Introduction: infantile hemangioma is the most common benign tumor in infancy. Currently, oral propranolol is the treatment of choice for infantile hemangioma, but there is no consensus when it comes to its recommended dosage for this condition. Hence this study was conducted to find out the appropriate dosage of oral propranolol for treatment of infantile hemangioma.
Methods: A prospective study was conducted on 25 patients with infantile hemangioma, who were treated with gradually increasing dose of propranolol starting from a lower dose of 1mg/kg/day.
Results: 17/22(76%) patients showed regression of the tumor at the dose of 1- 1.5 mg/kg/d. 5/22(24%) patients were unresponsive to the treatment with the lower dose and they did not respond even with the gradually escalated dose of 3-4 mg/kg/day.
Conclusion: Propranolol in a lower dose of 1-1.5 mg/kg/day is safe and efficacious in the treatment of infantile hemangioma and the lesions which do not show initial response to the lower dose are unlikely to respond to the higher dose of 3-4 mg/kg/day.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607273 | PMC |
| http://dx.doi.org/10.11604/pamj.2019.32.155.16760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary intrarenal hemangioma - A series of 39 cases.
Ann Diagn Pathol
January 2025
Department of Pathology and Laboratory Medicine, Brigham and Women's Hospital, Boston, USA. Electronic address:
Intrarenal hemangiomas lack concise clinicopathologic information, due to the predominance of single case reports and inclusion of other vascular neoplasms and hemangiomas of perirenal, hilar, and renal vein origin. Herein, in this multi-institutional study we evaluate clinicopathologic features of 39 intrarenal hemangiomas. The median age was 62 years (range = 27-94 years; 2:1 male to female ratio), with left-sided predominance (left = 21, right = 13; one case was bilateral).
View Article and Find Full Text PDFBenign eyelid lesions and its histopathological picture: A case-series.
J Family Med Prim Care
December 2024
Department of Ophthalmology, AL-Falah Medical College, Faridabad, Haryana, India.
Our prospective case series evaluates the clinical feature, histopathological picture, and treatment of benign eyelid lesions in a tertiary referral setting. Participants were first nine patients referred to the author with unilateral eyelid swelling. Main outcome measures were clinical features, histopathological picture, and response to surgical intervention.
View Article and Find Full Text PDFNeurodevelopmental Effects of Propranolol Treatment During Infancy in Infantile Hemangioma Patients.
Children (Basel)
December 2024
Department of Pediatric Hematology and Oncology, Istanbul Medical Faculty, İstanbul University, 34098 Istanbul, Turkey.
Introduction And Aim: Propranolol is an effective treatment option for infantile hemangiomas, but there is still insufficient information about neurodevelopmental side effects of propranolol. In our study, the neurodevelopmental levels of infantile hemangioma patients receiving propranolol treatment were examined using the Bayley-III test.
Method: In our single-center, cross-sectional study, patients were recruited between 1 January 2020 and 31 December 2023.
Efficacy and safety of propranolol tablets vs. oral solution in neonates with severe infantile hemangiomas: a retrospective study in China.
Sci Rep
January 2025
Department of Plastic Surgery, Jiangxi Provincial Children's Hospital, 1666 Diezihu Avenue, Nanchang, China.
The objective of this study was to evaluate the efficacy and safety of propranolol hydrochloride tablets and oral solution in neonates with severe IHs. A retrospective cohort study included 184 consecutive neonates diagnosed with severe IHs and treated with propranolol from January 2016 to June 2023. Of these, 126 patients received propranolol tablets, and 58 received propranolol oral solution.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!